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Turmeric (Curcuma longa) is extensively used as a 
spice, food preservative and colouring material in India, 
China and South East Asia. It has been used in tradi-
tional medicine as a household remedy for vari us 
diseases, including biliary disorders, anorexia, cough, 
diabetic wounds, hepatic disorders, rheumatism and 
sinusitis. For the last few decades, extensive work has 
been done to establish the biological activities and phar-
macological actions of turmeric and its extracts. Cur-
cumin (diferuloylmethane), the main yellow bioactive 
component of turmeric has been shown to have a wide 
spectrum of biological actions. These include its anti-
inflammatory, antioxidant, anticarcinogenic, antimuta-
genic, anticoagulant, antifertility, antidiabetic, antibac-
terial, antifungal, antiprotozoal, antiviral, antifibrotic, 
antivenom, antiulcer, hypotensive and hypocholestere-
mic activities. Its anticancer effect is mainly mediated 
through induction of apoptosis. Its antiinflammatory, 
anticancer and antioxidant roles may be clinically ex-
ploited to control rheumatism, carcinogenesis and oxi-
dative stress-related pathogenesis. Clinically, curcumin 
has already been used to reduce post-operative inflam-
mation. Safety evaluation studies indicate that both 
turmeric and curcumin are well tolerated at a very high 
dose without any toxic effects. Thus, both turmeric and 
curcumin have the potential for the development of 
modern medicine for the treatment of various diseases. 
INDIA has a rich history of using plants for medicinal pur-
poses. Turmeric (Curcuma longa L.) is a medicinal plant 
extensively used in Ayurveda, Unani and Siddha medicine 
as home remedy for various diseases1,2. C. longa L., bota-
nically related to ginger (Zingiberaceae family), is a per-
ennial plant having a short stem with large oblong leaves 
and bears ovate, pyriform or oblong rhizomes, which are 
often branched and brownish-yellow in colour. Turmeric 
is used as a food additive (spice), preservative and colour-
ing agent in Asian countries, includ ng China and South 
East Asia. It is also considered as auspicious and is a part 
of religious rituals. In old Hindu medicine, it is exten-
sively used for the treatment of sprains and swelling cau-
sed by injury1. In recent times, traditional Indian medicine 
uses turmeric powder for the treatment of biliary disorders, 
anorexia, coryza, cough, diabetic wounds, hepatic disorders, 
rheumatism and sinu itis3. In China, C. longa is used for 
diseases associated with abdominal pains4. The colouring 
principle of turmeric is the main component of this plant 
and is responsible for the antiinflammatory property. 
 Turmeric was described as C. longa by Linnaeus and its 
taxonomic position is as follows: 
 
Class Liliopsida 
Subclass Commelinids 
Order Zingiberales 
Family Zingiberaceae 
Genus Curcuma 
Species Curcuma longa 
 
The wild turmeric is called C. aromatica nd the domes-
tic species is called C. longa. 
Chemical composition of turmeric 
Turmeric contains protein (6.3%), fat (5.1%), minerals 
(3.5%), carbohydrates (69.4%) and moisture (13.1%). The 
essential oil (5.8%) obtained by steam distillation of rhi-
zomes has a-phellandrene (1%), sabinene (0.6%), cineol 
(1%), borneol (0.5%), zingiberene (25%) and sesquiterpin  
(53%)5. Curcumin (diferuloylmethane) (3–4%) is respon-
sible for the yellow colour, and comprises curcumin I 
(94%), curcumin II (6%) and curcumin III (0.3%)6. Deme-
thoxy and bisdemethoxy derivatives of curcumin have also 
been isolated7 (Figure 1). Curcumin was first isola ed8 in 
1815 and its chemical structure was determined by Roughley 
and Whiting9 in 1973. It has a melting point at 176–177°C; 
forms a reddish-brown salt with alkali and is soluble in 
ethanol, alkali, ketone, acetic acid and chloroform. 
Biological activity of turmeric and its compounds 
Turmeric powder, curcumin and its derivatives and many 
other extracts from the rhizomes were found to be bioac-
tive (Table 1). The structures of some of these compounds4 
are presented in Figure 1. Turmeric powder has healing 
effect on both aseptic and septic wounds in rats and rab-*For correspondence. (e-mail: ranajitb@yahoo.com) 
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bits10. It also shows adjuvant chemoprotection in experi-
mental forestomach and oral cancer models of Swiss mice 
and Syrian golden hamsters11. Curcumin also increases 
mucin secretion in rabbits12. Curcumin, the ethanol extract 
of the rhizomes, sodium curcuminate, [feruloyl-(4-hydroxy-
cinnamoyl)-methane] (FHM) and [bis-(4-hydroxycinna-
moyl)-methane] (BHM) and their derivatives, have high 
antiinflammatory activity against carrageenin-induced rat 
paw oedema13,14. Curcumin is also effective in formalin-
induced arthritis13. Curcumin reduces intestinal gas for-
mation15 and carbon tetrachloride and D-galactosamine-
induced glutamate oxaloacetate transaminase and glutamate 
pyruvate transaminase levels16,17. It also increases bile 
secretion in anaesthetized dogs 18 and rats19, and elvates 
the activity of pancreatic lipase, amylase, trypsin and chymo-
try sin20. Curcumin protects isoproterenol-induced myocar-
dial infarction in rats21. Curcumin, FHM and BHM also 
have anticoagulant activity22,23. Curcumin and an ether-
extract of C. longa have hypolipemic action in rats24 and 
lower cholesterol, fatty acids and triglycerides in alcohol-
induced toxicity25. Curcumin is also reported to have anti-
bacterial15, antiamoebic26 and antiHIV27 activities. Curcmin 
also shows antioxidant activity28–31. It also shows antitu-
mour32–34 and anticarcinogenic35–38 activities. The volatile 
oil of C. longa shows antiinflammatory39, antibacterial40,41 
and antifungal41 activities. The petroleum ether extract of 
C. longa is reported to have antiinflammatory activity42. 
Petroleum ether and aqueous extracts have 100% antiferti-
lity effects in rats43. Fifty per cent ethanolic extract of C.
longa shows hypolipemic action44 n rats. Ethanolic extract 
also possesses antitumour activity45. Alcoholic extract and 
sodium curcuminate can also offer antibacterial activity15,18. 
The crude ether andchloroform extracts of C. longa stem 
are also reported to have antifungal effects46. A C. longa 
fraction containing ar-turmerone has potent antivenom 
activity47. 
Pharmacological action of turmeric  
and its extract 
Several pharmacological activities and medicinal applica-
tions of turmeric are known1,2,4. Although curcumin has 
been isolated in the 19th century, extracts of the rhizomes 
of C. longa have been in use from the Vedic ages1,48. Some 
of the medicinal applications3 of turmeric are mentioned 
in Table 2. 
Pharmacological action of curcumin 
Effect on gastrointestinal system 
Stomach: Turmeric powder has beneficial effect on the 
stomach. It increases mucin secretion in rabbits and may 
thus act as gastroprotectant against irritants12. However, 
controversy exists regarding antiulcer activity of curcumin. 
Both antiulcer49 and ulcerogenic50,51 effects of curcumin 
have been reported but detailed studies are still lacking. 
Curcumin has been shown to protect the stomach from 
ulcerogenic effects of phenylbutazone in guinea pigs at 
50 mg/kg dose52,53. It also protects from 5-hydroxytrypta-
mine- induced ulceration at 20 mg/kg dose52,53. However, 
when 0.5% curcumin was used, it failed to protect against 
histamine-induced ulcers54. In fact, at higher doses of 50 mg/ 
kg and 100 mg/kg, it produces ulcers in rats51. Though the 
mechanism is not yet clear, an increase in the gastric acid 
and/or pepsin secretion and reduction in mucin content 
have been implicated in the induction of gastric ulcer55. 
Recent studies in our laboratory indicate that curcumin can 
block indomethacin, ethanol and stress-induced gastric ul er 
and can also prevent pylorus-ligation-induced acid secre-
 
Figure 1. Structure of natural curcuminoids. 
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tion in rats. The antiulcer effect is mediated by scaveng-
ing of reactive oxygen species by curcumin (unpubl shed 
observation). 
 
Intestine: Curcumin has some good effects on the intes-
tine also. Antispasmodic activity of sodium curcuminate 
was observed in isolated guinea pig ileum14. Antiflatulent 
activity was also observed in both in vivo and in vitro 
experiments in rats15. Curcumin also enhances intestinal 
lipase, sucrase and maltase activity56. 
 
Liver: Curcumin and its analogues have protective ac i-
vity in cultured rat hepatocytes against carbon tetrachlo-
ride, D-galactosamine, peroxide and ionophore-induced 
toxicity17,30,57. Curcumin also protects against diethylni-
trosamine and 2-acetylaminofluorine- duced altered 
hepatic foci development58. Increased bile production 
was reported in dogs by both curcumin and essential oil 
of C. longa19,59. 
Pancreas: 1-phenyl-1-hydroxy-n-pentane, a synthetic deri-
vative of p-tolylmethylcarbinol (an ingredient of C. longa) 
increases plasma secretion and bicarbonate levels60. Cur-
cumin also increases the activity of pancreatic lipase, amy-
lase, trypsin and chymotrypsin20. 
Effect on cardiovascular system 
Curcumin decreases the severity of pathological changes 
and thus protects from damage caused by myocardial in-
farction21. Curcumin improves Ca2+-transport and its slip-
page from the cardiac muscle sarcoplasmic reticulum, 
thereby raising the possibility of pharmacological inter-
ventions to correct the defective Ca2+ homeostasis in the 
cardiac muscle61. Curcumin has significant hypocholes-
teremic effect in hypercholesteremic rats62. 
Effect on nervous system 
Curcumin and manganese complex of curcumin offer pro-
tective action against vascular dementia by exerting anti-
oxidant activity63,64. 
Effect on lipid metabolism 
Curcumin reduces low density lipoprotein and very low 
density lipoprotein significantly in plasma and total cho-
lesterol levl in liver alongwith an increase of -tocopherol 
level in rat plasma, suggesting in vivo interaction between 
curcumin and a-tocopherol that may increase the bioavail-
ability of vitamin E and decrease cholesterol levels65. Cur-
cumin binds with egg and soy-phosphatidylcholine, which 
in turn binds divalent metal ions to offer antioxidant acti-
vity66. The increase in fatty acid content after ethanol-indu-
ced liver damage is significantly decreased by curcumin 
treatment and arachidonic acid level is increased67. 
Anti-inflammatory activity 
Curcumin is effective against carrageenin-induced oedema 
in rats13,14,68,69 and mice70. The natural analogues of cur-
cumin, viz. FHM and BHM, are also potent antiinflamma-
tory agents14. The volatile oil39 and also the petroleum 
ether, alcohol and water extracts of C. longashow antiin-
flammatory effects71. The antirheumatic activity of cur-
cumin has also been established in patients who showed 
significant improvement of symptoms after administration 
of curcumin72. That curcumin stimulates stress-induced 
expression of stress proteins and may act in a way similar 
Table 1. Biological activity of turmeric and its compounds 
   
   
Compound/extract Biological activity Reference 
      
Turmeric powder Wound-healing  10 
Ethanol extract Antiinflammatory 
Hypolipemic 
Antitumour 
Antiprotozoan 
 71 
 44 
 45 
 26 
 
Petroleum ether extract Antiinflammatory 
Antifertility 
 71 
 43 
 
Alcoholic extract Antibacterial  15 
 
Crude ether extract Antifungal  46 
 
Chloroform extract Antifungal  46 
 
Aqueous extract Antifertility  43 
 
Volatile oil Antiinflammatory 
Antibacterial 
Antifungal 
 39 
 15 
 41 
 
Curcumin Antibacterial 
Antiprotozoan 
Antiviral 
Hypolipemic 
Hypoglycemic 
Anticoagulant 
Antioxidant 
Antitumour 
Anticarcinogenic 
 40 
 15 
 27 
 24 
110 
 23 
  77,79 
  97,98 
 91 
 
Ar-turmerone Antivenom  47 
 
Methylcurcumin Antiprotozoan 123 
 
Demethoxycurcumin Antioxidant  29 
 
Bisdemethoxycurcumin Antioxidant  29 
 
Sodium curcuminate Antiinflammatory, antibacteri l  18 
   
   
 
Table 2. Medicinal properties of turmeric 
  
  
Turmeric finds medicinal 
applications in 
Anaemia, atherosclerosis, diabetes, oedema, 
haemorrhoids, hepatitis, hysteria, indigestio , 
inflammation, skin disease, urinary disease, 
wound and bruise healing, psoriasis, anorexia, 
cough, liver disorders, rheumatism, sinusitis 
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to indomethacin and salicylate, has recently been reported73. 
Curcumin offers antiinflammatory effect through inhibi-
tion of NFkB activation74. Curcumin has also been shown 
to reduce the TNF-a-induced expression of the tissue factor 
gene in bovine aortic-endothelial cells by repressing act-
vation of both AP-1 and NFkB75. The antiinflammatory 
role of curcumin is also mediated through downregulation 
of cyclooxygenase-2 and inducible nitric oxide synthe-
tase through suppression of NFkB activation34. Curcumin 
also enhances wound-healing in diabetic rats and mice76, 
and in H2O2-induced damage in human keratinocytes and 
fibroblasts31. 
Antioxidant effect 
The antioxidant activity of curcumin was reported77 as early 
as 1975. It acts as a scavenger of oxygen free radicals6,78.
It can protect haemoglobin from oxidation29. In vitro, cur-
cumin can significantly inhibit the generation of reactive 
oxygen species (ROS) like superoxide anions, H2O2 and 
nitrite radical generation by activated macrophages, which 
play an important role in inflammation79. Curcumin also 
lowers the production of ROS in vivo79. Its derivatives, 
demethoxycurcumin and bis- emethoxycurcumin also have 
antioxidant effect29,30. Curcumin exerts powerful inhibi-
tory effect against H2O2-induced damage in human kera-
tinocytes and fibroblasts31 and in NG 108-15 cells80. Cur-
cumin reduces oxidized proteins in amyloid pathology in 
Alzheimer transgenic mice81. It also decreases lipid per-
oxidation in rat liver microsomes, erythrocyte membranes 
and brain homogenates28. This is brought about by main-
taining the activities of antioxidant enzymes like super-
oxide dismutase, catalase and glutathione peroxidase82. 
Recently, we have observed that curcumin prevents oxida-
tive damage during indomethacin-induced gastric lesion 
not only by blocking inactivtion of gastric peroxidase, 
but also by direct scavenging of H2O2 and ·OH (unpub-
lished observation). Since ROS have been implicated in 
the development of various pathological conditions83–85, 
curcumin has the potential to control these diseases through 
its potent antioxidant activity. 
 Contradictory to the above-mentioned antioxidant effect, 
curcumin has pro-oxidant activity. Kelly et al.86 reported 
that curcumin not only failed to prevent single-strand DNA 
breaks by H2O2, but also caused DNA damage. As this 
damage was prevented by antioxidant a-tocopherol, the 
pro-oxidant role of curcumin has been proved. Curcumin 
also causes oxidative damage of rat hepatocytes by oxidi-
zing glutathione and of human erythrocyte by oxidizing
oxyhaemoglobin, thereby causing haemolysis87. The pro-
oxidant activity appears to be mediated through genera-
tion of phenoxyl radical of curcumin by peroxidas–H2O2 
system, whic cooxidizes cellular glutathione or NADH, 
accompanied by O2 uptake to form ROS
87. 
 The antioxidant mechanism of curcumin is attributed to 
its unique conjugated structure, which includes two meth-
oxylated phenols and an enol form of b-diketone; the struc-
ture shows typical radical-trapping ability as a chain-break-
ing antioxidant (Figure 1)88,89. Generally, the nonenzymatic 
antioxidant process of the phenolic mater al is hought to 
be mediated through the following two stages: 
 
S-OO° + AH ® SOOH + A° , 
A·  + X·  ® Nonradical materials, 
 
where S is the substance oxidized, AH is the phenolic anti-
oxidant, A·  is the antioxidant radical and X·  is another 
radical species or the same species90 as A· . A·  and X·  
dimerize to form the non-radical product. Masuda et al.89 
further studied the antioxidant mechanism of curcumin 
using linoleate as an oxidizable polyunsaturated lipid and 
proposed that the mechanism involves oxidative coupling 
reaction at the 3¢position of the cur min with the lipid 
and a subsequent intramolecular Diels–Alder reaction. 
Anticarcinogenic effect – induction of apoptosis 
Curcumin acts as a potent anticarcinogenic compound. 
Among various mechanisms, induction of apoptosis plays 
n important role in its anticarcinogenic effect. It induces 
apoptosis and inhibits cell-cyc e progression, both of which 
a e instrumental in preventing cancerous cell growth in rat 
aortic smooth muscle cells91. The antiproliferative eff ct is 
mediated partly through inhibition of protein tyrsine kinase 
and c-myc mRNA expression and the apoptotic effect may 
partly be mediated through inhibition of protein tyrsine
kinase, protein kinase C, c-myc mRNA expression and bcl-2 
mRNA expression91. Curcumin induces apoptotic cell death 
by DNA-damage in human cancer cell lines, TK-10, MCF-7 
and UACC-62 by acting as topoisomerase II poison92. 
Recently, curcumin has been shown to cause apoptosis in 
mouse neuro 2a cells by impairing the ubiquitin–protea-
some system through the mitochondrial pathway93. Cur-
cumin causes rapid decrease in mitochondrial membrane 
potential and release of cytchrome c to activate caspase 
9 and caspase 3 for apoptotic cell death93. R cently, an 
interesting observation was made regarding curcumin-in-
duced apoptosis in human colon cancer cell and role of 
heat shock proteins (hsp) thereon94. In this study, SW480 
cells were transfected with hsp 70 cDNA in either the sense 
or antisense orientation and stable clones were selected 
and tested for their sensitivity to curcumin. Curcumin was 
found to be ineffective to cause apoptosis in cells having 
hsp 70, while cells harbouring antisense hsp 70 were highly 
sensitive to apoptosis by curcumin as measured by nuclear 
condensation, mitochondrial transmembrane potential, re-
lease of cytochrome c, activation of caspase 3 and caspase 
9 and other parameters for apoptosis94. Expresion of glu-
tathione S-transferase P1-1 (GSTP1-1) is correlated to car-
cinogenesis and curcumin has been shown to induce apop-
tosis in K562 leukaemia cells by inhibiting the expression 
of GSTP1-1 at transcript on level95. The mechanism of cur-
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cumin-induced apotosis has also been studied in Caki 
cells, where curcumin causes apoptosis through down-
regulation of Bcl-XL and IAP, release of cyto hrome c 
and inhibition of Akt, which are markedly blocked y N-
acetylcysteine, indicating a role of ROS in curcumin-
induced cell death96. In LNCaP prostrate cancer cells, cur-
cumin induces apoptosis by enhancing tumour necrosis 
factor-related apotosis-inducing ligand (TRAIL)97. The 
combined treatment of the cell with curcumin and TRAIL 
induces DNA fragmentation, cleavage of procaspase 3, 8 
and 9, truncation of Bid and release of cytochrome c from 
mitochondria, indicating involvement of both external re-
ceptor-mediated and internal chemical-induced apotosis 
in these cells97. In colorectal carcinoma cell line, curcu-
min delays apopt sis along with the arrest of cell cycle at 
G1 phase
98. Curcumin also reduces P53 gene expression, 
which is accompanied with the induct on of HSP-70 gene 
through initial depletion98 f intracellular Ca2+. Curcumin 
also produces nonselective inhibition of proliferation in 
several leukaemia, nontransformed haematopoietic pr-
genitor cells and fibroblast cell lines99. That curcumin indu-
ces apoptosis and large-scale DNA fragmentation has also 
been observed in Vg9 d2+ T cells through inhibition of 
isopentenyl pyrophosphate-induced NFkB activation, proli-
feration and chemokine producti n100. Curcumin induces 
apoptosis in human leukaemia HL-60 cells, which is bloc-
ked by some antioxidants35. Colon carcinoma is also pre-
vented by curcumin through arrest of cell-cycle progression 
independent of inhibition of prostaglandin synthesis101. 
Curcumin suppresses human breast carcinom  through 
multiple pathways. Its antiproliferative effect is estrogen-
dependent in ER (estrogen receptor)-positive MCF-7 cells 
and estrogen-independent in ER-negative MDA-MB-231 
cells37. Curcumin also downregulates matrix metallopro-
teinase (MMP)-2 and upregulates tissue inhibitor of met-
alloproteinase (TIMP)-1, two common effector molecules 
involved in cell invasion37. It also induces apoptosis through 
P53-dependent Bax induction in human breast cancer cells38. 
However, curcumin affects different cell lines differently. 
Whereas leukaemia, breast, colon, hepatocellular and ova-
rian carcinoma cells undergo apoptosis in the presence of 
curcumin, lung, prostate, kidney, cervix and CNS malig-
nancies and melanoma cells show resistance to cytotoxic 
effect of curcumin102. 
 Curcumin also suppresses tumour growth through vari-
ous pathways. Nitric oxide (NO) and its derivatives play 
a major role in tumour promotion. Curcumin inhibits iNOS 
and COX-2 production69 by suppression of NFkB activa-
tion34. Curcumin also increases NO production in NK cells 
after prolonged treatment, culminating in a stronger tumou-
ricidal effect33. Curcumin also induces apoptosis in AK-5 
tumour cells through upregulation103 of caspase-3. Reports 
also exist indicating that curcumin blocks dexamethasone-
induced apoptosis of rat thymocytes104,105. Recently, in 
Jurkat cells, curcumin has been shown to prevent gluta-
thione depletion, thus protecting cells from caspase-3 
activation and oligonucleosomal DNA fragmenttion106. 
Curcumin also inhibits proliferation of rat thymocy es104. 
These strongly imply that cell growth and cell death share  
common pathway at some point and that curcumin affects 
a common step, presumably involving modulation of AP-1 
transcription factor104,106. 
Pro/antimutagenic activity 
Curcumin exerts both pro- and antimutagenic effects. At 
100 and 200 mg/kg body wt doses, curcumin has been 
shown to reduce the number of aberrant cells in cyclo-
phosphamide-induced chromosomal aberration in Wistar 
rats107. Turmeric also prevents mutation in urethane (a 
powerful mutagen) models108. Contradictory reports also 
exist. Curcumin and turmeric enhance g-r diation-induced 
chromosome aberration in Chinese hamster ovary109. Cur-
cumin has also been shown to be non-protective against 
hexavalent chromium- nduced DNA strand break. In fact, 
the total effect of chromium and curcumin is additive in 
causing DNA breaks in human lymphocytes and gastric 
mucosal cells110. 
Anticoagulant activity 
Curcumin shows anticoagulant activity by inhibiting col-
lagen and adrenaline-induced platelet aggregation in vitro 
as well as in vivo in rat thoracic aorta23. 
Antifertility activity 
Petroleum ether and aqueous extracts of turmeric rhizo-
mes show 100% antifertility effect in rats when fed orally43. 
Implantation is completely inhibited by these extracts111. 
Curcumin inhibits 5a-reductase, which onverts testote-
rone to 5a-dihydrotestosterone, thereby inhi iting the growth 
of flank organs in hamster112. Curcumin also inhibits human 
sperm motility and has the potential for the development 
of a novel intravaginal contraceptive113. 
Antidiabetic effct 
Curcumin prevents galactose-induced cataract formation 
at very low doses114. Both turmeric and curcumin decrease 
blood sugar level in alloxan-induced diabetes in rat115. Cur-
cumin also decreases advanced glycation end products-
induced complications in d abetes mellitus116. 
Antibacterial activity 
Both curcumin and the oil fraction suppress growth of 
several bacteria like Streptococcus, Staphylococcus, Lac-
tob cillus, etc.15. The aqueous extract of turmeric rhizomes 
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has antibacterial effects117. Curcumin also prevents growth 
of Helicobacter pylori CagA+ strains in vitro118. 
Antifungal effect 
Ether and chloroform extracts and oil of C. longa have 
antifungal effects41,46,119. Crude ethanol extract also pos-
sesses antifungal activity120. Turmeric oil is also active 
against Aspergillus flavus, A. parasiticus, Fusarium moni-
liforme and Penicillium digitatum121. 
Antiprotozoan activity 
The ethanol extract of the rhizomes has anti-Entamoeba 
histolytica ctivity. Curcumin has anti-Leishmania ctiv-
ity in vitro122. Several synthetic derivatives of curcumin 
have anti-L. amazonensis effect123. Anti-Plasmodium falci-
parum and anti-L. major effects of curcumin have also been 
reported124. 
Antiviral effect 
Curcumin has been shown to have antiviral activity4. It acts 
as an efficient inhibitor of Epstein-Barr virus (EBV) key 
activator Bam H fragment z left frame 1 (BZLF1) protein 
transcription in Raji DR-LUC cells125. EBV inducers such 
as 12-0-tetradecanoylphorbol-13-acetate, sodium butyrate 
and transforming growth factor-beta increase the level of 
BZLF1 m-RNA at 12–48 h after treatment in these cells, 
which is effectively blocked by curcumin125. Most impor-
tantly, curcumin also shows anti-HIV (human immunodefi-
ciency virus) activity by inhibiting the HIV-1 integrase 
needed for viral replication27,126. It also inhibits UV light-
induced HIV gene expression127. Thus curcumin and its ana-
logues may have the potential for novel drug development 
against HIV. 
Antifibrotic effect 
Curcumin suppresses bleomycin-induced pulmonary fibro-
sis in rats128. Oral administration of curcumin at 300 mg/kg 
dose inhibits bleomycin-induced increase in total cell counts
and biomarkers of inflammatory responses. It also sup-
preses bleomycin-i duced alveolar macrophage-produc-
tion of TNF-a, superoxide and itric oxide. Thus curcumin 
acts as a potent antiinflammatory and antifibrotic agent. 
Antivenom effect 
Ar-turmerone, isolated from C. longa, neutralizes both hae-
morrhagic activity of B throps venom and 70% lethal ef-
fect of Crotalus venom in mice4. It acts as an enzymatic 
inhibitor of venom enzymes with proteolytic activities47. 
Pharmacokinetic studies on curcumin 
Curcumin, when given orally or intraperitoneally to rats, 
is mostly egested in the faeces and only a little in the 
urine129,130. Only traces of curcumin are found in the blood
from the heart, liver and kidney. Curcumin, when added 
to isolated hepatocytes, is quickly metabolized and the 
major biliary metabolites are glucuronides of tetrahydro-
curcumin and hexahydrocurcumin131,132. Curcumin, after 
metabolism in the liver, is mainly excreted through bile. 
Clinical studies and medicinal applications of 
turmeric and curcumin 
Although various studies have been carried out with tur-
meric extracts and some of its ingredients in several animal 
models1,4,133, only a few clinical studies are reported so far. 
Turmeric 
Powdered rhizome is used to treat wounds, bruises, infla-
med joints and sprains134 in Nepal. In current tradi ional 
Indian medicine, it is used for the treatment of biliary dis-
orders, anorexia, cough, diabetic wounds, hepatic disorders, 
rheumatism and sinusitis48. Data are also available show-
ing that the powder, when applied as capsules to patients 
with respiratory disease, gives relief from symptom  like 
dyspnoea, cough and sputum135. A short clinical trial in 
18 patients with definite rheumatoid arthritis showed signi-
ficant improvement in morning stiffness and joint swelling 
after two weeks of therapy with oral doses of 120 mg/ 
day53. Application of the powder in combination with 
other plant products is also reported for purification of 
blood and for menstrual and abdominal problems136. 
Curcumin 
In patients undergoing surgery, oral application of curcu-
min reduces post- perative inflammation137. Recently, cur-
cumin has been formulated as slow-release biodegrad ble 
microspheres for the treatment of inflammation in arth-
ritic rats138. It is evident from the study that curcumin-
biodegradable microspheres could be successfully emplo-
yed for therapeutic management of inflammation138. 
Safety evaluation with turmeric and curcumin 
Detailed studies have been reported on the safety evalua-
tion of the rhizomes of C. longa and its alcohol extract, 
curcumin132,139. The major findings are presented below. 
Turmeric 
The average intake of turmeric by Asians varies from 0.5 
to 1.5 g/day/person, which produces no toxic symptoms2. 
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Male and female Wistar rats, guinea pigs and monkeys were 
fed with turmeric at much higher doses (2.5 g/kg body wt) 
than normally consumed by humans. No changes were 
observed in the appearance and weight of kidney, liver and 
heart132. Also, no pathological or behavioural abnormali-
ties were noticed and no mortality was observed. 
Curcumin 
Curcumin was given to Wistar rats, guinea pigs and mon-
keys of both sexes at a dose of 300mg/kg body wt. No 
pathological, behavioural abnormalities or lethality was 
observed133. No adverse effects were observed on both 
growth and the level of erythrocytes, leucocytes, blood 
constituents such as haemoglobin, total serum protein, alka-
line phosphatase, etc.139. Human clinical trials also indicate 
that curcumin has no toxicity when administered at doses 
of 1–8 g/day140 and 10 g/day141. 
Future prospects 
Turmeric has been used in ayurvedic medicine since anci-
ent times, with various biological applications. Although 
some work has been done on the possible medicinal appli-
cations, no studies for drug- evelopment have been car-
ried out as yet. Although the crude extract has numerous 
medicinal applications, clinical applications can be made 
only after extensive research on its bioactivity, mechanism 
of action, pharmacotherapeutics and toxicity studies. How-
ever, as curcumin is now available in pure form, which 
shows a wide spectrum of biological activities, it would 
be easier to develop new drugs from this copound after 
extensive studies on its mechanism of action and phar-
macological effects. Recent years have seen an increased 
enthusiasm in treating various diseases with natural pro-
ducts. Curcumin is a non-toxic, highly promising natural 
antioxidant compound having a wide spectrum of bio-
logical functions. It is expected that curcumin may find 
application as a novel drug in the near future to control
various diseases, including inflammatory disorders, car-
cinogenesis and oxidative stress-induced pathogenesis. 
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